A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma
Muzaffar H. Qazilbash(The University of Texas MD Anderson Cancer Center), Larry W. Kwak(The University of Texas MD Anderson Cancer Center), Veerabhadran Baladandayuthapani(University of Michigan), Adam D. Cohen(Penn Center for AIDS Research), Szymon J. Szymura(City of Hope), Edward A. Stadtmauer(University of Pennsylvania), Bruce L. Levine(University of Pennsylvania), Alfred L. Garfall(University of Pennsylvania), Neeraj Saini(The University of Texas MD Anderson Cancer Center), Robert Z. Orlowski(University of North Carolina at Chapel Hill), Dan T. Vogl(University of Pennsylvania), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Aaron Anderson(City of Hope), Elizabeth J. Shpall(Scripps MD Anderson Cancer Center), Beryl Tross(The University of Texas MD Anderson Cancer Center), Karen Dengel(Parker Institute for Cancer Immunotherapy), Qaiser Bashir(The University of Texas MD Anderson Cancer Center), Heather Lin(The University of Texas MD Anderson Cancer Center), Kunhwa Kim(The University of Texas MD Anderson Cancer Center), Michael Popescu(The University of Texas MD Anderson Cancer Center), Zhe Wang(The Nature Conservancy), Soung-chul Cha(The University of Texas MD Anderson Cancer Center), Naseem Kerr(Parker Institute for Cancer Immunotherapy), Tiantian Zhang(University of Jinan), Carl H. June(University of Pennsylvania), Sheetal Rao(The University of Texas MD Anderson Cancer Center), Medhavi Honhar(The University of Texas MD Anderson Cancer Center)
Cited by 24
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
CAR T Cells Produced in vivo to Treat Cardiac Injury
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|940